Zirgan Gel
NDC Package 24208-535-32
Package Information
Zirgan (ganciclovir) gel is ganciclovir is used to treat herpes infection of the eye. This formulation utilizes a gel delivery system. Marketed by Bausch & Lomb Incorporated, this product is identified by NDC 24208-535 and is authorized under FDA application NDA022211.
Identification & Billing
- RxCUI: 388052 - ganciclovir 0.15 % Ophthalmic Gel
- RxCUI: 388052 - ganciclovir 0.0015 MG/MG Ophthalmic Gel
- RxCUI: 864650 - Zirgan 0.15 % Ophthalmic Gel
- RxCUI: 864650 - ganciclovir 0.0015 MG/MG Ophthalmic Gel [Zirgan]
- RxCUI: 864650 - Zirgan 0.0015 MG/MG Ophthalmic Gel
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 24208 - Bausch & Lomb Incorporated
- 24208-535 - Zirgan
- 24208-535-32 - 1 TUBE, WITH APPLICATOR in 1 CARTON / 1 g in 1 TUBE, WITH APPLICATOR
- 24208-535 - Zirgan
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (24208-535). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 24208-535-32 identifies a specific commercial package of 1 tube, with applicator in 1 carton / 1 g in 1 tube, with applicator of Zirgan, a human prescription drug labeled by Bausch & Lomb Incorporated. This gel is formulated for ophthalmic use and contains ganciclovir as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Bausch & Lomb Incorporated on April 30, 2010. The current certification is valid through December 31, 2027.
What are the primary indications for this medication?
Ganciclovir is used to treat herpes infection of the eye. Although ganciclovir stops the growth of the virus, it is not a cure for the herpes infection. Herpes virus continues to live in the body even between outbreaks of infection. However, treating an outbreak may help the sores in the eye to heal faster and lower the risk of complications (such as decreased vision, blindness). Ganciclovir is an anti-viral drug. This medication treats only herpes eye infections. It will not work for other types of eye infections, such as those caused by bacteria. Unnecessary use or misuse of any anti-infective drug can lead to its decreased effectiveness.
How is this Bausch & Lomb Incorporated product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 24208053532. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.